Investors

Press Releases

 
Press Releases
  Date Title View
Apr 5, 2010
RESEARCH TRIANGLE PARK, N.C. – April 5, 2010 – Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company’s cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vien...
Mar 30, 2010
RESEARCH TRIANGLE PARK, N.C. – March 30, 2010 – Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company’s lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams’ Hepatitis C Conference on Thursday, April 1, 2010 at 11:...
Mar 24, 2010
RESEARCH TRIANGLE PARK, NC (May 24, 2010) – Drug discovery and development company SCYNEXIS on Thursday will lead a discussio...
Dec 17, 2009
RESEARCH TRIANGLE PARK, N.C., (Dec. 17, 2009) – Drug discovery and development company SCYNEXIS, Inc. announced today that it has achieved a third milestone in its collaboration with Merck & Co., Inc. to develop novel antifungal agents. This latest milestone payment was triggered following the initiation of clinical ...
Dec 16, 2009
RESEARCH TRIANGLE PARK, N.C. (Dec. 16, 2009) SCYNEXIS, Inc., a fully integrated drug discovery and development company, today announced that the U.S. Food and Drug Administration (FDA) completed its cGMP compliance inspection of the SCYNEXIS Process Chemistry, Analytical and Manufacturing facilities. The FDA performed both a g...
Nov 4, 2009
RESEARCH TRIANGLE PARK, N.C., and DULUTH, GA., Nov. 4, 2009 – Merial Limited and SCYNEXIS, Inc. announced today that SCYNEXIS has earned a payment for meeting certain milestones in its multi-year research collaboration with Merial Limited, which began in 2005. SCYNEXIS, a premier drug discovery and development company, f...
Nov 3, 2009
Research Triangle Park, NC (November 3, 2009) – Drug discovery company SCYNEXIS, Inc. today presented positive data from an in vitro study evaluating the antiviral activity of SCY-635 in combination with approved and investigational nonnucleoside polymerase inhibitors, nucleoside polymerase inhibitors, protease ...
Oct 27, 2009
RESEARCH TRIANGLE PARK (October 27, 2009) – Drug discovery company SCYNEXIS, Inc. today announced that it has received a payment from Merck & Co., Inc. for achieving a preclinical milestone resulting from a collaboration to discover and develop novel oncology agents. “We are pleased to celebrate success...
May 13, 2009
RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA (May 13, 2009) – SCYNEXIS, Inc. and Medicines for Malaria Venture (MMV) announced today that they have signed an agreement giving MMV access to SCYNEXIS’ proprietary HEOS® drug discovery software platform for use in the organization’s anti-malarial research pro...
Apr 24, 2009
Research Triangle Park, NC (April 24, 2009) – Drug discovery company SCYNEXIS, Inc. today presented positive results from a Phase 1b single-agent, randomized, double-blind, placebo-controlled study of its lead, oral, antiviral drug candidate, SCY-635, in adult patients with genotype 1 chronic hepatitis C infection. SCY-6...
FirstPrevious ...
12
NextLast
= add release to Briefcase